Filing Flows › Metagenomi Therapeutics (MGX) › Q2 2025
Metagenomi Therapeutics (MGX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Metagenomi Therapeutics (MGX) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -57% from a year earlier and +106% from the quarter before. Operating margin was -246.5%, net loss $19.9M (233.9% of revenue).
Metagenomi Therapeutics, Q2 2025: revenue $8.5M (-58% year over year), operating margin -246.5%, net loss $19.9M, operating cash flow −$21.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5M | +106% | -57% |
| Operating profit | −$21.0M | — | — |
| Net earnings | −$19.9M | — | — |
| Operating cash flow | −$21.3M | — | — |
What changed
Revenue was $8.5M in Q2 2025, down 57% year over year and up 106% from the previous quarter.
Operating costs exceeded revenue by $21.0M, an operating margin of -246.5%. Total costs fell 20% while revenue fell 57%. The quarter ended with a net loss of $19.9M, narrower than the previous quarter's $25.0M loss.
Operating cash flow was −$21.3M. Non-cash charges added back $1.3M of depreciation and $3.2M of share-based compensation. Working capital and other items used $5.9M. Capital expenditures of $127K exceeded it, leaving free cash flow of −$21.4M.
Questions
What was Metagenomi Therapeutics' revenue in the second quarter 2025?
Metagenomi Therapeutics (MGX) reported revenue of $8.5M for the second quarter 2025 (Q2 2025), -57% from a year earlier and +106% from the quarter before.
Was Metagenomi Therapeutics profitable in the second quarter 2025?
Operating loss was $21.0M (-246.5% of revenue) and net loss $19.9M.